Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Entreprise · 15/12/20001 min de lecture
Draft Guidance for Industry on Botanical Drug Products; Availability; Reopening of Comment Period
Traduction automatique locale · Langue originale de la source
Résumé
The Food and Drug Administration (FDA) is reopening the comment period for the draft guidance for industry entitled "Botanical Drug Products" until March 15, 2001. This draft guidance explains the circumstances under which FDA approval of a new drug application (NDA) is required for marketing of a botanical drug product and when such a product may be marketed under an over-the-counter (OTC) drug monograph. It also provides guidance to researchers and manufacturers on conducting initial and expanded clinical investigations of botanical drug products. FDA is taking this action in response to a request for an extension.
Langue originale de la source: Federal Register — Food and Drug AdministrationOuvrir le communiqué original →